FDA Extends Review Of AstraZeneca's Camizestrant NDA In ESR1-Mutated Advanced Breast Cancer

AstraZeneca said the FDA will extend the PDUFA date to review additional data supporting the NDA for Camizestrant in combination with a CDK4/6 inhibitor. The delay pushes out the regulatory timeline and adds uncertainty around approval timing, but the update does not indicate a rejection or safety issue. The news is modestly negative for sentiment and may pressure shares slightly, though the broader market impact should be limited.

Analysis

AstraZeneca said the FDA will extend the PDUFA date to review additional data supporting the NDA for Camizestrant in combination with a CDK4/6 inhibitor. The delay pushes out the regulatory timeline and adds uncertainty around approval timing, but the update does not indicate a rejection or safety issue. The news is modestly negative for sentiment and may pressure shares slightly, though the broader market impact should be limited.